{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:17:03Z","timestamp":1788239823619,"version":"build-2803163510"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metastatic colorectal cancer (mCRC) is associated with poor prognosis and low survival rates, with acquired resistance limiting the durability of standard therapies. Mesenchymal-epithelial transition factor (MET) amplification is a rare but potentially actionable molecular alteration that has been implicated in treatment resistance, while clinical evidence supporting MET-directed combination therapy in mCRC remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      We report a rare case of a young patient with KRAS\/NRAS\/BRAF wild-type descending colon cancer with liver metastases and\n                      <jats:italic>de novo<\/jats:italic>\n                      MET amplification detected in the pretreatment primary tumor. After achieving stable disease with second-line FOLFIRI plus bevacizumab, savolitinib, a highly selective MET tyrosine kinase inhibitor (TKI), was added to the ongoing regimen. The patient subsequently achieved marked radiologic and pathological regression during combination treatment, suggesting a possible additive contribution of MET inhibition.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings suggest that the addition of savolitinib to standard chemotherapy and a VEGF inhibitor may have contributed additional antitumor activity in this patient with MET-amplified mCRC. However, the independent contribution of savolitinib cannot be determined, and this observation should be regarded as hypothesis-generating and warrants validation in prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1861675","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:27:19Z","timestamp":1788236839000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Remarkable response to savolitinib plus chemotherapy and bevacizumab in second-line treatment of MET amplified colon cancer with liver metastasis"],"prefix":"10.3389","volume":"16","author":[{"given":"Ying","family":"Huang","sequence":"first","affiliation":[{"name":"Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital of Sichuan University","place":["Chengdu, China"]},{"name":"Department of Radiation Oncology, Cancer Center, West China Hospital of Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Shu","sequence":"additional","affiliation":[{"name":"Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital of Sichuan University","place":["Chengdu, China"]},{"name":"Department of Radiation Oncology, Cancer Center, West China Hospital of Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyuan","family":"Gu","sequence":"additional","affiliation":[{"name":"Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital of Sichuan University","place":["Chengdu, China"]},{"name":"Department of Radiation Oncology, Cancer Center, West China Hospital of Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wen","sequence":"additional","affiliation":[{"name":"Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital of Sichuan University","place":["Chengdu, China"]},{"name":"Department of Radiation Oncology, Cancer Center, West China Hospital of Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital of Sichuan University","place":["Chengdu, China"]},{"name":"Department of Radiation Oncology, Cancer Center, West China Hospital of Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.0106","article-title":"Diagnosis and treatment of metastatic colorectal cancer: a review","volume":"325","author":"Biller","year":"2021","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0029","article-title":"Colon cancer, version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Benson","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.33.5091","article-title":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status","volume":"29","author":"Van Cutsem","year":"2011","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-01577-5","article-title":"The role of MET in chemotherapy resistance","volume":"40","author":"Wood","year":"2021","journal-title":"Oncogene"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2013.12.014","article-title":"The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance","volume":"142","author":"Maroun","year":"2014","journal-title":"Pharmacol Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/1010428317699118","article-title":"The c-Met receptor: implication for targeted therapies in colorectal cancer","volume":"39","author":"Safaie Qamsari","year":"2017","journal-title":"Tumour Biol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.40","article-title":"Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges","volume":"14","author":"Bradley","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0377-z","article-title":"MET-dependent solid tumours - molecular diagnosis and targeted therapy","volume":"17","author":"Guo","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.22316","article-title":"Role of HGF\/c-Met in the treatment of colorectal cancer with liver metastasis","volume":"33","author":"Yao","year":"2019","journal-title":"J Biochem Mol Toxicol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01584-0","article-title":"Savolitinib: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(24)00211-x","article-title":"Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study","volume":"12","author":"Yu","year":"2024","journal-title":"Lancet Respir Med"},{"key":"B13","volume-title":"Ajcc Cancer Staging Manual","author":"Amin","year":"2017"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35726","article-title":"DNA damage response and repair gene mutations predict clinical outcomes in biliary tract cancer","volume":"131","author":"Tan","year":"2025","journal-title":"Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30049","article-title":"A randomized, placebo-controlled, phase 1\/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy","volume":"139","author":"Eng","year":"2016","journal-title":"Int J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0223","article-title":"A phase II randomized trial (GO27827) of first-line FOLFOX plus bevacizumab with or without the MET inhibitor onartuzumab in patients with metastatic colorectal cancer","volume":"22","author":"Bendell","year":"2017","journal-title":"Oncologist"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13707","article-title":"College of American Pathologists tumor regression grading system for long-term outcome in patients with locally advanced rectal cancer","volume":"26","author":"Chen","year":"2021","journal-title":"Oncologist"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i12.3706","article-title":"Prognostic value of c-Met in colorectal cancer: a meta-analysis","volume":"21","author":"Liu","year":"2015","journal-title":"World J Gastroenterol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-022-04404-8","article-title":"Cabozantinib with or without panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers","volume":"89","author":"Jia","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.10.016","article-title":"A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification","volume":"87","author":"Angevin","year":"2017","journal-title":"Eur J Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-024-01156-x","article-title":"A phase 2 study of savolitinib in patients with MET amplified metastatic colorectal cancer","volume":"56","author":"Jia","year":"2024","journal-title":"J Gastrointest Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-1337","article-title":"A multicenter phase II study of AMG 337 in patients with MET-amplified gastric\/gastroesophageal junction\/esophageal adenocarcinoma and other MET-amplified solid tumors","volume":"25","author":"Van Cutsem","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103668","article-title":"A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17)","volume":"9","author":"Kang","year":"2024","journal-title":"ESMO Open"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1177\/1758835919889001","article-title":"A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma","volume":"11","author":"Qin","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-14-1293","article-title":"Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic","volume":"20","author":"Jardim","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000032368","article-title":"Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: a real-life data of Turkish Oncology Group","volume":"101","author":"G\u00fcrb\u00fcz","year":"2022","journal-title":"Med (Baltimore)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-1189","article-title":"First-in-human phase I study of the selective MET inhibitor, savolitinib, in patients with advanced solid tumors: safety, pharmacokinetics, and antitumor activity","volume":"25","author":"Gan","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14254","article-title":"Phase 1 study of capmatinib in MET-positive solid tumor patients: dose escalation and expansion of selected cohorts","volume":"111","author":"Bang","year":"2020","journal-title":"Cancer Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-1341","article-title":"Phase I study of AMG 337, a highly selective small-molecule MET inhibitor, in patients with advanced solid tumors","volume":"25","author":"Hong","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-021-00568-w","article-title":"MET-targeted therapies and clinical outcomes: a systematic literature review","volume":"26","author":"Dong","year":"2022","journal-title":"Mol Diagn Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231221910","article-title":"MET alterations detection platforms and clinical implications in solid tumors: a comprehensive review of literature","volume":"16","author":"Yuan","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrc3205","article-title":"Targeting MET in cancer: rationale and progress","volume":"12","author":"Gherardi","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-15-0748","article-title":"Molecular heterogeneity and receptor coamplification drive resistance to targeted therapy in MET-amplified esophagogastric cancer","volume":"5","author":"Kwak","year":"2015","journal-title":"Cancer Discov"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2147\/JEP.S242958","article-title":"MET inhibitors for the treatment of gastric cancer: what's their potential","volume":"12","author":"El Darsa","year":"2020","journal-title":"J Exp Pharmacol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1158\/2159-8290.cd-22-0586","article-title":"Osimertinib + savolitinib to overcome acquired MET-mediated resistance in epidermal growth factor receptor-mutated, MET-amplified non-small cell lung cancer: TATTON","volume":"13","author":"Hartmaier","year":"2023","journal-title":"Cancer Discov"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2018.77.7326","article-title":"Phase Ib\/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer","volume":"36","author":"Wu","year":"2018","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3318","article-title":"Randomized trial of tepotinib plus gefitinib versus chemotherapy in EGFR-mutant NSCLC with EGFR inhibitor resistance due to MET amplification: INSIGHT final analysis","volume":"29","author":"Liam","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-020-00928-z","article-title":"A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment","volume":"38","author":"Delord","year":"2020","journal-title":"Invest New Drugs"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdae220","article-title":"A phase Ib study evaluating the c-MET inhibitor INC280 (capmatinib) in combination with bevacizumab in patients with high-grade glioma","volume":"7","author":"Falchook","year":"2024","journal-title":"Neuro-Oncol Adv"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.5580","article-title":"Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, MET-positive gastroesophageal adenocarcinoma: the METGastric randomized clinical trial","volume":"3","author":"Shah","year":"2017","journal-title":"JAMA Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2017.08.044","article-title":"Recent advances in the discovery of small molecule c-Met kinase inhibitors","volume":"143","author":"Parikh","year":"2018","journal-title":"Eur J Med Chem"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.2147\/ott.s44941","article-title":"Emerging molecular targets in oncology: clinical potential of MET\/hepatocyte growth-factor inhibitors","volume":"7","author":"Smyth","year":"2014","journal-title":"Onco Targets Ther"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17091493","article-title":"Targeting c-MET alterations in cancer: a review of genetic drivers and therapeutic implications","volume":"17","author":"Ji","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B44","doi-asserted-by":"publisher","first-page":"4708","DOI":"10.3390\/cancers15194708","article-title":"Savolitinib: a promising targeting agent for cancer","volume":"15","author":"Lee","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.7150\/jca.20964","article-title":"Synergistic antitumor effects of cMet inhibitor in combination with anti-VEGF in colorectal cancer patient-derived xenograft models","volume":"9","author":"Chen","year":"2018","journal-title":"J Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-013-0486-y","article-title":"FOLFIRI + bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials","volume":"30","author":"Beretta","year":"2013","journal-title":"Med Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-011-0331-2","article-title":"Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial","volume":"17","author":"Horita","year":"2012","journal-title":"Int J Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.140","article-title":"Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial","volume":"108","author":"Nasti","year":"2013","journal-title":"Br J Cancer"},{"key":"B49","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13046-017-0591-4","article-title":"High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods","volume":"36","author":"Su","year":"2017","journal-title":"J Exp Clin Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1001\/jamaoncol.2016.3797","article-title":"Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials","volume":"3","author":"Tejpar","year":"2017","journal-title":"JAMA Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1861675\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:27:24Z","timestamp":1788236844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1861675\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":50,"alternative-id":["10.3389\/fonc.2026.1861675"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1861675","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"1861675"}}